Oncotelic Therapeutics Inc. has announced the completion of subscription agreements with certain accredited investors for a private placement, issuing a total of 11 units as part of an offering of up to 500 units. Each unit consists of a $25,000 note bearing 12% annual interest, convertible into either 250,000 shares of Oncotelic's common stock at $0.10 per share or 25,000 shares of EdgePoint AI, Inc., a subsidiary, at $1.00 per share. The units also include warrants to purchase additional shares of Oncotelic or EdgePoint. The securities were sold in reliance on exemptions from registration under the Securities Act of 1933 and are not registered for public sale. Existing investors in a prior 2023 note offering were also able to exchange their notes for new units and convert EdgePoint shares into Oncotelic shares at a specified rate. The company also entered into a Registration Rights Agreement in connection with the offering.